Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia (Q44653678)

5 December 2017

Role of the TRAIL/APO2-L death receptors in chlorambucil- and fludarabine-induced apoptosis in chronic lymphocytic leukemia (English)

1 reference

5 December 2017

9

1 reference

5 December 2017

James B Johnston

1

1 reference

5 December 2017

Albert F Kabore

2

1 reference

5 December 2017

Jeanna Strutinsky

3

1 reference

5 December 2017

Xiaojie Hu

4

1 reference

5 December 2017

James T Paul

5

1 reference

5 December 2017

Dianne M Kropp

6

1 reference

5 December 2017

Brenda Kuschak

7

1 reference

5 December 2017

Asher Begleiter

8

1 reference

5 December 2017

language of work or name

English

0 references

publication date

1 November 2003

1 reference

5 December 2017

1 reference

5 December 2017

22

1 reference

5 December 2017

51

1 reference

5 December 2017

8356-8369

1 reference

https://scigraph.springernature.com/pub.10.1038/sj.onc.1207004

5 December 2017

0 references

cites work

Apoptosis control by death and decoy receptors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

Safety and antitumor activity of recombinant soluble Apo2 ligand

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

An inducible pathway for degradation of FLIP protein sensitizes tumor cells to TRAIL-induced apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

Retinoic acid-induced apoptosis in leukemia cells is mediated by paracrine action of tumor-selective death ligand TRAIL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Chlorambucil in chronic lymphocytic leukemia: mechanism of action

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

TRAIL receptor-2 signals apoptosis through FADD and caspase-8

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Ionizing radiation sensitizes erythroleukemic cells but not normal erythroblasts to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cytotoxicity by selective up-regulation of TRAIL-R1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

When and how to treat chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Genomic aberrations and survival in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Nucleotide requirements for the in vitro activation of the apoptosis protein-activating factor-1-mediated caspase pathway

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Increased expression of death receptors 4 and 5 synergizes the apoptosis response to combined treatment with etoposide and TRAIL

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

In leukaemic CD5+ B cells the expression of BCL-2 gene family is shifted toward protection from apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Evidence that the human death receptor 4 is regulated by activator protein 1

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Inhibition of death receptor signals by cellular FLIP

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Caspase 8 activation independent of Fas (CD95/APO-1) signaling may mediate killing of B-chronic lymphocytic leukemia cells by cytotoxic drugs or gamma radiation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

c-Jun-dependent CD95-L expression is a rate-limiting step in the induction of apoptosis by alkylating agents

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

p53 abnormalities in CLL are associated with excess of prolymphocytes and poor prognosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Use of serum-free media to minimize apoptosis of chronic lymphocytic leukemia cells during in vitro culture

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

TRAIL-induced eradication of primary tumour cells from multiple myeloma patient bone marrows is not related to TRAIL receptor expression or prior chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Mechanisms of resistance to TRAIL-induced apoptosis in primary B cell chronic lymphocytic leukaemia.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

TRAIL/Apo2L ligand selectively induces apoptosis and overcomes drug resistance in multiple myeloma: therapeutic applications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Intracellular regulation of tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human multiple myeloma cells

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Sensitization to TRAIL-induced apoptosis and modulation of FLICE-inhibitory protein in B chronic lymphocytic leukemia by actinomycin D.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Antisense-mediated suppression of Bcl-2 highlights its pivotal role in failed apoptosis in B-cell chronic lymphocytic leukaemia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

TRAIL (Apo2L) suppresses growth of primary human leukemia and myelodysplasia progenitors

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-kappaB

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Identification of a commonly deleted region at 17p13.3 in leukemia and lymphoma associated with 17p abnormality

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Mechanisms of p53-dependent apoptosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Positive and negative regulation of apoptotic pathways by cytotoxic agents in hematological malignancies.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Wild-type p53 transactivates the KILLER/DR5 gene through an intronic sequence-specific DNA-binding site.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

TRAIL receptor and CD95 signal to mitochondria via FADD, caspase-8/10, Bid, and Bax but differentially regulate events downstream from truncated Bid

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

KILLER/DR5, a novel DNA-damage inducible death receptor gene, links the p53-tumor suppressor to caspase activation and apoptotic death

1 reference

https://api.crossref.org/works/10.1038%2FSJ.ONC.1207004

7 January 2021

Identifiers

DOI

10.1038/SJ.ONC.1207004

1 reference

5 December 2017

1 reference